Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial
复制标题
利妥昔单抗在有或没有 IgG4 自身抗体的难治性 CIDP 中的疗效和安全性 (RECIPE):双盲、随机、安慰剂对照临床试验方案
DOI:
10.2196/17117
复制
发表时间:
2020
影响因子:
1.7
通讯作者:
Katsuno Masahisa
中科院分区:
文献类型:
--
作者:
Shimizu Shinobu;Iijima Masahiro;Fukami Yuki;Tamura Natsuko;Nakatochi Masahiro;Ando Masahiko;Nishi Ryoji;Koike Haruki;Kaida Kenichi;Koga Michiaki;Kanda Takashi;Ogata Hidenori;Kira Jun-Ichi;Mori Masahiro;Kuwabara Satoshi;Katsuno Masahisa
登录
查看更多内容
影响因子:
9.9
作者:
T. Levine;A. Pestronk
通讯作者:
A. Pestronk
影响因子:
11
作者:
Chio, A.;Cocito, D.;Calvo, A.
通讯作者:
Calvo, A.
影响因子:
4.4
作者:
C. Münch;Pedros Anagnostou;R. Meyer;J. Haas
通讯作者:
J. Haas
影响因子:
3.3
作者:
C. Melendez;J. Redford;P. Choudhary;I. Gray;Philip Maitland;N. Gregson;Kenneth J. Smith;R. Hughes
通讯作者:
R. Hughes
DOI:
10.1016/j.ejpn.2011.08.002
发表时间:
2012
期刊:
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
影响因子:
--
作者:
A. D’Amico;M. Catteruccia;F. De Benedetti;M. Vivarelli;M. Colucci;S. Cascioli;E. Bertini
通讯作者:
E. Bertini